Author | Kenneth J. Bender, PharmD, MA


Adverse Effects Reduce Drug Efficacy in OCD

February 09, 2016

A study of treatment tolerance and therapeutic response in children and adolescents with OCD.

New Analysis of Antidepressants in Pregnancy Finds Little Added Risk of Newborn Pulmonary Hypertension

July 29, 2015

An overview of the largest study to examine persistent pulmonary hypertension in newborns (PPHN) exposed to antidepressants late in pregnancy.

Large Trials for First-Episode Psychosis: One Debuts, Another Marks 10 Years

May 19, 2015

Progress in identifying and effectively treating first-episode schizophrenia was marked by the simultaneous publication of a report on a 6-year study and on the 10-year follow-up of a large-scale trial.

Olanzapine/Fluoxetine Combination Affirmed for Bipolar Depression

July 16, 2013

A recent meta-analysis supports evidence of the effectiveness of the fixed olanzapine/fluoxetine combination (Symbyax) in treating the depressive phase of bipolar disorder. Response was ranked higher, but with no more adverse effects, than with treatment with olanzapine alone.

“PRN” Medication for Alcohol Dependence May Reduce Harm

June 18, 2013

In a new study, "as needed" use of an opioid antagonist for heightened alcohol craving appeared to reduce the number of heavy drinking days and total amount of alcohol consumed.

No Mortality Increase With Antipsychotics in Prospective Study

June 17, 2013

Results of a 10-week prospective study, recently reported at the Annual Meeting of the American Association for Geriatric Psychiatry, offered no conclusive evidence about the mortality risk of elderly patients with Alzheimer disease who were treated with antipsychotics.

Irreversible Monoamine Oxidase Inhibitors Revisited

October 08, 2012

Given the likelihood that insufficient numbers of patients will be available for a randomized controlled trial of MAOIs in refractory depression or atypical depression, we must still rely on consensus guidelines and expert opinion.

FDA Panel Votes to Curtail Cranial Electrotherapy Stimulators

July 14, 2012

The FDA Neurological Devices Panel met to consider the Agency’s proposal to reclassify cranial electrotherapy stimulator (CES) devices to Class III with premarket approval.

Reviewers Question Utility of Clinical Trials in Schizophrenia

April 03, 2012

Much could be gained if an agreed minimum set of appropriate and important outcomes was measured and reported in all clinical trials in a particular area.

Refeeding Regimens for Anorexia Challenged

February 09, 2012

A new study examining conventional “start low, go slow” nutrition replenishment protocols for hospitalized patients with anorexia nervosa (AN) that have been recommended by professional organizations and it's outcomes.